[go: up one dir, main page]

UY33372A - ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. - Google Patents

?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.

Info

Publication number
UY33372A
UY33372A UY0001033372A UY33372A UY33372A UY 33372 A UY33372 A UY 33372A UY 0001033372 A UY0001033372 A UY 0001033372A UY 33372 A UY33372 A UY 33372A UY 33372 A UY33372 A UY 33372A
Authority
UY
Uruguay
Prior art keywords
compositions
manufacture
quinolina
medicines
understand
Prior art date
Application number
UY0001033372A
Other languages
English (en)
Inventor
William R Baker
Cai Shaopei
Joshua Aaron Kaplan
Kim Musong
Jennifer Alissa Loyer-Drew
Perrault Stephane
Phillips Gary
Lafe J Purvis Ii
Stasiak Marcin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY33372A publication Critical patent/UY33372A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan compuestos análogos de quinolina bi-funcionales, así como también su uso en la manufactura de un medicamento para el tratamiento de la inflamación pulmonar o de la broncoconstricción y composiciones que los comprenden y procesos para su preparación.
UY0001033372A 2010-05-10 2011-05-09 ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. UY33372A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33302010P 2010-05-10 2010-05-10
US40693010P 2010-10-26 2010-10-26
US201161477263P 2011-04-20 2011-04-20

Publications (1)

Publication Number Publication Date
UY33372A true UY33372A (es) 2011-12-30

Family

ID=44072535

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033372A UY33372A (es) 2010-05-10 2011-05-09 ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.

Country Status (9)

Country Link
US (2) US8394829B2 (es)
EP (1) EP2569285A1 (es)
JP (2) JP5807058B2 (es)
AR (1) AR081026A1 (es)
AU (1) AU2011253203A1 (es)
CA (1) CA2796826A1 (es)
NZ (1) NZ603136A (es)
UY (1) UY33372A (es)
WO (1) WO2011143105A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5807058B2 (ja) * 2010-05-10 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 二機能キノリン誘導体
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
BR112016017996A2 (pt) * 2014-02-06 2017-08-08 Abbvie Inc 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
JP6125467B2 (ja) * 2014-06-16 2017-05-10 富士フイルム株式会社 プリント注文受付機とその作動方法および作動プログラム
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN112250557A (zh) * 2020-10-23 2021-01-22 徐州工程学院 一种高效合成1,6-二烯-3-酮衍生物的方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US3885047A (en) 1972-06-16 1975-05-20 Mead Johnson & Co Ocular hypotensive process employing dextrorotatory phenethanolamines
US4145542A (en) 1974-06-13 1979-03-20 Otsuka Pharmaceutical Co., Ltd. 5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US4761421A (en) 1985-05-08 1988-08-02 Merck & Co., Inc. Use of certain compounds in livestock food as growth promotants for better feed utilization and improved carcass composition
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
DE69232034T2 (de) 1991-12-18 2002-06-06 Minnesota Mining And Mfg. Co., Saint Paul Aerosolzusammensetzungen für Arzneimittelsuspensionen
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
US5712298A (en) 1993-07-02 1998-01-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
AP960A (en) 1995-04-14 2001-04-20 Glaxo Wellcome Inc Metered dose inhaler for fluticasone propionate.
AU5772196A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
BR9709105A (pt) 1996-05-20 1999-08-03 Darwin Discovery Ltd Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv
ATE406163T1 (de) 1996-05-20 2008-09-15 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
NZ527232A (en) * 1998-08-26 2005-03-24 Smithkline Beecham Corp A composition contaning a PDE 4 inhibitor and a beta adrenergic bronchodilator useful for treating pulmonary diseases
US6262070B1 (en) 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
US6329034B1 (en) 1999-01-18 2001-12-11 Roger L. Pendry Label having tab member and methods for forming, applying and using the same
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
BR0011343A (pt) 1999-06-05 2002-03-12 Innovata Biomed Ltd Dispositivo de distribuição de medicamento,e,métodos de administrar um medicamento por inalação,e de,tratamento de um paciente com distúrbio respiratório
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
TR200909479T2 (tr) 1999-08-21 2012-02-21 Nycomed Gmbh Sinerjistik kombinasyon.
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
ATE271400T1 (de) 1999-10-12 2004-08-15 Shl Medical Ab Inhalateur
GB9928265D0 (en) 1999-12-01 2000-01-26 Innovata Biomed Ltd Inhaler
JP2003512640A (ja) 1999-12-08 2003-04-02 クゥアルコム・インコーポレイテッド クライアント装置に広告を配布するためのｅ−メールソフトウェアおよびその方法とシステム
SE9904706D0 (sv) 1999-12-21 1999-12-21 Astra Ab An inhalation device
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
PL358057A1 (en) * 2000-06-05 2004-08-09 Altana Pharma Ag Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
FR2813593B1 (fr) 2000-09-07 2002-12-06 Valois Sa Dispositif de distribution de produit fluide de type multidose
GB0026647D0 (en) 2000-10-31 2000-12-13 Glaxo Group Ltd Medicament dispenser
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
ES2242036T3 (es) 2001-06-27 2005-11-01 MERCK FROSST CANADA & CO. Inhibidores pde4 de arilquinolina 8-sustituida.
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7144896B2 (en) 2002-03-18 2006-12-05 Merck Frosst Canada Ltd. Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
US6889690B2 (en) 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
AU2003239880A1 (en) * 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
ES2282667T3 (es) 2002-06-25 2007-10-16 Merck Frosst Canada Ltd. Inhibidores de pde4 8-(biaril)quinolinas.
US20060040981A1 (en) 2002-11-22 2006-02-23 Daniel Dube Use of phosphodiesterase-4 inhibitors as enhancers of cognition
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
CA2523336A1 (en) 2003-04-30 2004-11-11 Merck Frosst Canada Ltd. 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
TWI328009B (en) * 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1488819A1 (en) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
EP1833822A2 (en) * 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
GB0503955D0 (en) 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
CA2617286A1 (en) * 2005-08-01 2007-02-08 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20100004215A1 (en) 2005-10-19 2010-01-07 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
CA2639925C (en) 2006-01-24 2016-07-12 Nexbio, Inc. Technology for preparation of macromolecular microspheres
JP2009118740A (ja) 2006-03-03 2009-06-04 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
GB0605462D0 (en) 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
EA016203B1 (ru) * 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина
JP5254961B2 (ja) 2006-06-09 2013-08-07 パリオン・サイエンシィズ・インコーポレーテッド ベータアゴニスト活性を有するフェニル置換ピラジノイルグアニジンナトリウムチャネル遮断薬
CA2657093A1 (en) 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
JP2010534563A (ja) 2007-07-24 2010-11-11 ネクスバイオ，インク． マイクロ粒子の作製のための技術
WO2009100169A1 (en) 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
WO2009142589A1 (en) 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) * 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
UY32521A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Combinación para emplear en el tratamiento de enfermedades respiratorias
WO2011143106A1 (en) * 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
JP5807058B2 (ja) * 2010-05-10 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 二機能キノリン誘導体

Also Published As

Publication number Publication date
US20130012504A1 (en) 2013-01-10
JP5807058B2 (ja) 2015-11-10
CA2796826A1 (en) 2011-11-17
AU2011253203A1 (en) 2012-11-22
US20110275622A1 (en) 2011-11-10
WO2011143105A1 (en) 2011-11-17
EP2569285A1 (en) 2013-03-20
JP2015131833A (ja) 2015-07-23
JP2013526520A (ja) 2013-06-24
NZ603136A (en) 2014-11-28
US8394829B2 (en) 2013-03-12
AR081026A1 (es) 2012-05-30

Similar Documents

Publication Publication Date Title
UY33372A (es) ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CO2017011851A2 (es) Compuestos novedosos
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CR20150326A (es) Inhibidores de autotaxina
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CL2013000352A1 (es) Compuesto derivado de isoxazolina como agentes antiparasitarios; composicion farmaceutica o veterinaria que comprende el compuesto; uso del compuesto para preparar un medicamento.
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
DOP2013000307A (es) Antagonistas de trpv4
CL2014002505A1 (es) Compuestos derivados de piridopirimidina substituida, como inhibidores de flt3; formulacion farmaceutica que los comprende; y su uso para el tratamiento de tumores hematologicos malignos tal como leucemias, enfermedades autoinmunes y tumores solidos malignos.
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
NI201700052A (es) Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CR20150171A (es) Benzamidas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200626